SCHEMBL21045149

SCHEMBL21045149

Cc1cc(C(=O)NCCCc2ccc(-c3ccccc3F)cc2)no1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.56
FAAH O00519 4/20 0.55
TDP1 Q9NUW8 1/20 0.53
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C19 P33261 1/20 0.51
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MAPT P10636 1/20 0.48
GAA P10253 1/20 0.48
GFER P55789 1/20 0.48
HIF1A Q16665 3/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
TSHR P16473 1/20 0.47
TP53 P04637 1/20 0.46
HTT P42858 1/20 0.46
CNR1 P21554 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29411461 1.00 LMNA (0.56) LMNAFAAHTDP1CYP1A2CYP2D6
SCHEMBL29411596 0.86 FAAH (0.76) LMNAFAAHTDP1NPC1RAB9A
SCHEMBL21045410 0.86 FAAH (0.76) LMNAFAAHTDP1NPC1RAB9A
SCHEMBL21045118 0.86 POLB (0.50) FAAHTDP1NPC1RAB9ASMN1; SMN2
SCHEMBL29411496 0.86 POLB (0.50) FAAHTDP1NPC1RAB9ASMN1; SMN2
SCHEMBL21100382 0.85 FAAH (0.42) LMNAFAAHTDP1CYP1A2CYP2D6
SCHEMBL29411570 0.84 MAPT (0.52) LMNAFAAHTDP1NPC1RAB9A
SCHEMBL21045132 0.84 MAPT (0.52) LMNAFAAHTDP1NPC1RAB9A
SCHEMBL21045493 0.82 TSHR (0.72) NPC1RAB9ASMN1; SMN2MAPTGAA
SCHEMBL29411444 0.82 TSHR (0.72) NPC1RAB9ASMN1; SMN2MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220089539-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2022-03-24 US disclosed
US-20220089539-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2022-03-24 US disclosed
US-11040945-B2 Tubulin inhibitors LIN BIOSCIENCE PTY LTD. 2021-06-22 US disclosed
US-11040945-B2 Tubulin inhibitors LIN BIOSCIENCE PTY LTD. 2021-06-22 US disclosed
WO-2019113242-A1 TUBULIN INHIBITORS Lin BioScience, LLC (US) 2019-06-13 WO disclosed
US-20190169127-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2019-06-06 US disclosed
US-20190169127-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2019-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089539-A1 TUBULIN INHIBITORS TUBB3, TUBB1, TUBB LMNA 2547/4885FAAH 4071/4885TDP1 302/4885
US-11040945-B2 Tubulin inhibitors TUBB3, TUBB1, TUBB LMNA 2547/4885FAAH 4071/4885TDP1 302/4885
US-20190169127-A1 TUBULIN INHIBITORS TUBB3, TUBB1, TUBB LMNA 2547/4885FAAH 4071/4885TDP1 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.